<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782323</url>
  </required_header>
  <id_info>
    <org_study_id>V201_01</org_study_id>
    <nct_id>NCT04782323</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults</brief_title>
  <official_title>A Phase 2, Randomized, Observer-blind, Antigen and Adjuvant Dose Ranging Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59 Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults ≥50 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, randomized, observer-blind, antigen and adjuvant dose-ranging Clinical study is&#xD;
      evaluating different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated&#xD;
      Influenza Vaccine. Approximately 800 subjects are to be randomized into 1 of 8 possible&#xD;
      treatment groups. Immunogenicity and safety will be assessed in the overall study population&#xD;
      (adults ≥50 years and above) and in the age subgroups ≥50-64 years and ≥65 years to determine&#xD;
      the appropriate age population for this vaccine. Data from this study will be used to select&#xD;
      the optimal dose to be tested in the pivotal Phase 3 immunogenicity and safety study in older&#xD;
      adults.&#xD;
&#xD;
      Disclosure Statement: This is a parallel-group dose-ranging study with 8 arms that is&#xD;
      participant, investigator and observer-blinded.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">October 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a parallel-group dose-ranging study with 8 arms that is participant, investigator and observer-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure: 1. Immunogenicity Endpoint: Hemagglutination inhibition (HI) titers against vaccine A and B influenza strains</measure>
    <time_frame>[28 days post-vaccination]</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">839</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group A aQII-1 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B aQII-3 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C aQII-6 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D aQII-7 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E aQII-9 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F aQII-10 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G aQII-11 Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H QII Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aQII-1</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group A aQII-1 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aQII-3 Investigational</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group B aQII-3 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aQII-6 Investigational</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group C aQII-6 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>aQII-7 Investigational</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group D aQII-7 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aQII-9 Investigational</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group E aQII-9 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aQII-10 Investigational</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group F aQII-10 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aQII-11 Investigational</intervention_name>
    <description>Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group G aQII-11 Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QII Active Comparator</intervention_name>
    <description>Biological/Vaccine: Investigational QII Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.</description>
    <arm_group_label>Group H QII Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        In order to participate in this study, all subjects must meet ALL of the inclusion criteria&#xD;
        described.&#xD;
&#xD;
          1. Individuals ≥50 years of age on the day of informed consent.&#xD;
&#xD;
          2. Individuals who have voluntarily given written consent after the nature of the study&#xD;
             has been explained according to local regulatory requirements, prior to study entry.&#xD;
&#xD;
          3. Individuals who can comply with study procedures including follow-up .&#xD;
&#xD;
          4. Males, females of non-childbearing potential or females of childbearing potential who&#xD;
             are using an effective birth control method, at least 30 days prior to informed&#xD;
             consent, which they intend to use for at least 2 months after the study vaccination.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        In order to participate in this study, all subjects must not meet ANY of the exclusion&#xD;
        criteria described below:&#xD;
&#xD;
          1. Females of childbearing potential who are pregnant, lactating, or who have not adhered&#xD;
             to a specified set of contraceptive methods from at least 30 days prior to informed&#xD;
             consent and who do not plan to do so for at least 2 months after the study&#xD;
             vaccination.&#xD;
&#xD;
          2. Progressive, unstable or uncontrolled clinical conditions.&#xD;
&#xD;
          3. Hypersensitivity, including allergy, to any component of vaccines whose use is&#xD;
             foreseen in this study.&#xD;
&#xD;
          4. History of any medical condition considered an adverse event of special interest&#xD;
             (AESI) (see Appendix 2 - List of Adverse Events of Special Interest).&#xD;
&#xD;
          5. Known history of Guillain-Barré syndrome or another demyelinating disease such as&#xD;
             encephalomyelitis and transverse myelitis.&#xD;
&#xD;
          6. Clinical conditions representing a contraindication to intramuscular administration of&#xD;
             vaccines or blood draw.&#xD;
&#xD;
          7. Abnormal function of the immune system resulting from:&#xD;
&#xD;
               1. Clinical conditions.&#xD;
&#xD;
               2. Systemic administration of corticosteroids (PO/IV/IM) at a dose of ≥20 mg/day of&#xD;
                  prednisone or equivalent for more than 14 consecutive days within 90 days prior&#xD;
                  to informed consent5.&#xD;
&#xD;
               3. Administration of antineoplastic and immunomodulating agents or radiotherapy&#xD;
                  within 90 days prior to informed consent.&#xD;
&#xD;
          8. Receipt of immunoglobulins or any blood products within 180 days prior to informed&#xD;
             consent.&#xD;
&#xD;
          9. Receipt of an investigational or non-registered medicinal product within 30 days prior&#xD;
             to vaccination.&#xD;
&#xD;
         10. Individuals who received any other vaccines within 14 days (for inactivated vaccines)&#xD;
             or 28 days (for live vaccines) prior to enrolment in this study or who are planning to&#xD;
             receive any vaccine within 28 days from the study vaccines.&#xD;
&#xD;
         11. Study personnel or immediate family or household member of study personnel.&#xD;
&#xD;
         12. Receipt of any influenza vaccine within 6 months prior to vaccination in this study,&#xD;
             or plan to receive an influenza vaccine during the study period.&#xD;
&#xD;
         13. Acute (severe) febrile illness (see Section 4.3, Criteria for Delay of Vaccination).&#xD;
&#xD;
         14. Any other clinical condition that, in the opinion of the investigator, might interfere&#xD;
             with the results of the study or pose additional risk to the subject due to&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Therapeutic Area Head</last_name>
    <role>Study Chair</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>03607 - PCRN_Paratus Clinical Research</name>
      <address>
        <city>Bruce</city>
        <state>Canberra</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03605 - PCRN_Paratus Clinical Research (Central Coast)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3610- Emeritis Research</name>
      <address>
        <city>Botany</city>
        <state>New South Wales</state>
        <zip>2019</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3609 - Northern Beaches Clinical Research [NSW]</name>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <zip>2100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03602 - PCRN_Paratus Clinical Research,(Western Sydney) [NSW]</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03608 - Australian Clinical Research Network - ACRN [NSW]</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03604 - University of the Sunshine Coast Clinical Trials Centre</name>
      <address>
        <city>Morayfield</city>
        <state>Queensland</state>
        <zip>4506</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03603 - University of the Sunshine Coast</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03601 - AusTrials Taringa [QLD]</name>
      <address>
        <city>Taringa</city>
        <state>Queensland</state>
        <zip>4068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03606 - AusTrials Tarragindi (Aus Trial Wellers Hill)[QLD]</name>
      <address>
        <city>Tarragindi</city>
        <state>Queensland</state>
        <zip>4121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3611 - The University of Melbourne Peter Doherty Institute for Infection and Immunity</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55402- PCRN_Southern Clinical Trials Waitemata</name>
      <address>
        <city>Birkenhead</city>
        <state>Auckland</state>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55401- PCRN_Southern Clinical Trials Totara</name>
      <address>
        <city>New Lynn</city>
        <state>Auckland</state>
        <zip>0600</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55406 - Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55404- PCRN_Southern Clinical Trials Christchurch</name>
      <address>
        <city>Christchurch</city>
        <zip>8013</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55403-PCRN_Lakeland Clinical Trials Waikato</name>
      <address>
        <city>Hamilton</city>
        <zip>3200</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55405 - PCRN_Lakeland Clinical Trials</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60801 - De La Salle Medical and Health Sciences Institute</name>
      <address>
        <city>Dasmariñas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60802 - West Visayas University Medical Center</name>
      <address>
        <city>Jaro</city>
        <state>Iloilo City</state>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60805 - Manila Doctors' Hospital</name>
      <address>
        <city>Ermita</city>
        <state>Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60804 - Quirino Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>Quezon</state>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60803 - Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71003- Newtown Clinical Research</name>
      <address>
        <city>Newtown</city>
        <state>Johannesburg</state>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71005 South Africa Haylene71005 - Tiervlei Trial Centre -- Karl Bremer Hospital</name>
      <address>
        <city>Bellville</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71002 - JOSHA Research</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71011 - Farmovs</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71004 - Tread Research -- Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71006 - Mzansi Ethical Research Centre (MERC)</name>
      <address>
        <city>Mpumalanga</city>
        <zip>1050</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71009 - Be Part Yoluntu Centre</name>
      <address>
        <city>Paarl</city>
        <zip>7626</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71001 - Wits Clinical Researc - Chris Hani Baragwanath Academic Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.&#xD;
Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry [EU CTR])</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Time Frame:&#xD;
SEQIRUS discloses results from clinical studies within 12 months of last patient last visit (LPLV) unless otherwise mandated by local laws or regulations.</ipd_time_frame>
    <ipd_access_criteria>SEQIRUS will consider requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the United States (US) and/or the European Union (EU). This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication</ipd_access_criteria>
    <ipd_url>https://www.seqirus.us/partnering</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

